Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.

@article{Dahlf1998CharacteristicsO9,
  title={Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.},
  author={Bj{\"o}rn Dahl{\"o}f and Richard Blyton Devereux and Stevo Julius and Sverre Erik Kjeldsen and Gareth D Beevers and Ulf H de Faire and Frej Y Fyhrquist and Thomas Hedner and Hans Henning Windel\ov Ibsen and Krister J. Kristianson and Ole Lederballe-Pedersen and Lars Lindholm and Markku S Nieminen and Per Omvik and Suzanne Oparil and Hans Wedel},
  journal={Hypertension},
  year={1998},
  volume={32 6},
  pages={989-97}
}
-Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension. The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of the beta-blocker atenolol on the reduction of cardiovascular morbidity and mortality. Patients with essential hypertension, aged between 55 and 80 years… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 103 extracted citations

Similar Papers

Loading similar papers…